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Historical background
A delicate balance between bone resorption and bone for-
mation is critical for the maintenance of bone strength and
integrity, wherein bone-resorbing osteoclasts and bone-
forming osteoblasts play central roles [1]. In fact, this
physiologic process, termed bone remodeling, must be
regulated strictly, and tipping the balance in favor of
osteoclasts causes bone destruction observed in patho-
logical conditions such as autoimmune arthritis, perio-
dontitis, postmenopausal osteoporosis, Paget’s disease
and bone tumors [2,3].
RANKL (receptor activator of nuclear factor κB ligand), a
member of the TNF (tumor necrosis factor) family, is an
essential cytokine for the differentiation of monocyte/
macrophage precursors to osteoclasts [4–6]. Briefly,
binding of RANKL to its receptor, RANK (receptor activa-
tor of nuclear factor κB), results in the recruitment of
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Chapter summary
Regulation of osteoclast differentiation is an aspect central to the understanding of the pathogenesis
and the treatment of bone diseases such as autoimmune arthritis and osteoporosis. In fact, excessive
signaling by RANKL (receptor activator of nuclear factor κB ligand), a member of the tumor necrosis
factor (TNF) family essential for osteoclastogenesis, may contribute to such pathological conditions.
Here we summarize our current work on the negative regulation of osteoclastogenesis by unique
signaling crosstalk between RANKL and interferons (IFNs). First, activated T cells maintain bone
homeostasis by counterbalancing the action of RANKL through production of IFN-γ. This cytokine
induces rapid degradation of the RANK (receptor activator of nuclear factor κB) adapter protein
TRAF6 (TNF-receptor-associated factor 6), resulting in strong inhibition of the RANKL-induced
activation of NF-κB and JNK (c-Jun N-terminal kinase). Second, RANKL induces the IFN-β gene but
not IFN-α genes, in osteoclast precursor cells, and that IFN-β strongly inhibits the osteoclast
differentiation by interfering with the RANKL-induced expression of c-Fos. The series of in vivo
experiments revealed that these two distinct IFN-mediated regulatory mechanisms are both important
to maintain homeostasis of bone resorption. Collectively, these studies revealed novel aspects of the
two types of IFN, beyond their original roles in the immune response, and may offer a molecular basis
for the treatment of bone diseases.
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proteins of the TRAF (TNF-receptor-associated factor)
family, such as TRAF6, which activates NF-κB and JNK (c-
Jun N-terminal kinase) pathways [7–9]. By a yet unknown
mechanism, RANKL also induces expression of c-Fos
[10,11]. The essential role of these TRAF6 and c-Fos
pathways in osteoclastogenesis has been well docu-
mented by gene disruption studies [12–15]. To maintain
normal bone homeostasis, this RANKL signaling must be
properly regulated. In this context, osteoprotegerin (OPG),
a soluble ‘decoy’ receptor for RANKL, is known as a nega-
tive regulator of osteoclastogenesis [16]. In fact, mice
lacking OPG develop osteoporosis, suggesting that the
balance between RANKL and OPG dictates the levels of
bone resorption [17].
It has been reported that prolonged or aberrant activation
of the immune system in certain autoimmune conditions
often results in tissue destruction mediated by effector
cells. In fact, enhanced osteoclastic bone resorption
causes severe bone damage leading to progressive joint
destruction in autoimmune arthritis [18,19], wherein T-cell
expression of RANKL may play a critical role. In this
context, it has been reported that activated T cells
promote osteoclastogenesis through expression of
RANKL in vitro [18,20]. However, it is not known whether
activated T cells maintain bone homeostasis by counter-
balancing the action of RANKL.
One may infer that the process of osteolastogenesis is
under negative regulation by factors in addition to OPG, at
multiple levels, in order to maintain bone homeostasis.
Regulation of osteoclastogenesis by T cells
via IFN-γ γ
Involvement of the T-cell-produced IFN-γ γ in negative
regulation of osteoclastogenesis
To study whether activated T cells contribute in the regula-
tion of osteoclastogenesis, we used a well-established
model of endotoxin-induced bone resorption, in which the
essential involvement of T cells has been documented
[21,22]. A notable exacerbation of osteoclast formation
and bone destruction was observed in mice lacking
IFNGR1, one of the components of IFN-γ receptor
(IFNGR) (IFN-γR–/– mice) [8]. This observation is also con-
sistent with an enhanced severity in the T-cell-mediated
collagen-induced model of autoimmune arthritis observed
in IFN-γR–/– mice [23,24]. When the effect of IFN-γ-
producing T cells on osteoclastogenesis was examined in
vitro, osteoclast formation from RANKL-stimulated bone-
marrow-derived monocyte/macrophage precursor cells
(BMMs) was strongly inhibited by the coculture with T
cells activated with the anti-CD3 antibody but not with
resting T cells. When activated T cells were cocultured
with IFN-γR–/– BMMs, however, the inhibitory effect of acti-
vated T cells was completely abrogated. These IFN-γR–/–
BMMs differentiated into osteoclasts, albeit with low effi-
ciency, when cocultured with activated T cells, even in the
absence of recombinant RANKL, suggesting that the
effect of T cells on osteoclastogenesis depends on the
balance between RANKL and IFN-γ. Activated T-cell
supernatant also suppressed osteoclastogenesis induced
by recombinant RANKL, and this suppressive activity was
inhibited by a neutralizing antibody against IFN-γ. These
results collectively indicate that IFN-γ is critical for T-cell
suppression of RANKL-induced osteoclastogenesis.
Mechanism of action of IFN-γ γ
A marked inhibitory effect of IFN-γ was observed by an in
vitro assay for osteoclast formation in RANKL-stimulated
BMMs, and a very low level of IFN-γ strongly inhibited
osteoclast formation even in the presence of an excess
amount of RANKL. The cytokine signals the cell through
activation of the transcription factor STAT1 (signal trans-
ducer and activator of transcription 1) [25]. The active
form of this transcription factor, termed IFN-γ-activated
factor (GAF), induces target genes of IFN-γ either directly
or through the induction of the transcription factor IRF-1
(interferon regulatory factor 1) [26]. The inhibitory effect of
IFN-γ on osteoclastogenesis was completely abrogated in
STAT1–/– mice but not in IRF-1–/– mice. Thus, the STAT1
(GAF)-mediated, IRF-1-independent gene induction
pathway is critical for interfering with the RANKL signaling
pathway.
To investigate the target of IFN-γ inhibition of osteoclasto-
genesis, RANKL-induced activation of NF-κB and JNK
was examined in IFN-γ-treated BMMs. It was found that
RANKL-induced activation of NF-κB and JNK was
markedly inhibited in IFN-γ-treated BMMs and that this
inhibition was accompanied by strong suppression of
TRAF6 expression. Notably, overexpression of TRAF6 in
BMMs by retrovirus-mediated gene transfer rendered
them resistant to IFN-γ-mediated inhibition of osteoclasto-
genesis. In these cells, RANKL-induced activation of
NF-κB and JNK was also restored, indicating further that
TRAF6 is the critical target of the action of IFN-γ. Thus,
downregulation of TRAF6 expression accounts, at least in
part, for the IFN-γ inhibition of osteoclastogenesis.
The mechanism by which TRAF6 expression is downregu-
lated by IFN-γ was investigated further. It was found that
TRAF6 protein levels, rather than its mRNA levels, were
suppressed after RANKL stimulation in the presence of
IFN-γ. Interestingly, stimulation by RANKL per se pro-
moted TRAF6 degradation, which was markedly acceler-
ated by IFN-γ. Since the TRAF6 level is upregulated during
stimulation by RANKL, the equilibrium of TRAF6 protein is
apparently shifted toward its synthesis rather than its
degradation in the absence of IFN-γ, but the addition of
IFN-γ reverses the equilibrium. Notably, IFN-γ alone had no
effect on TRAF6 expression, suggesting that accelerated
TRAF6 degradation by IFN-γ requires RANKL signaling.S229
Further studies revealed that TRAF6 is a direct target for
the ubiquitin–proteasome system, which is enhanced by
IFN-γ [8] (Fig. 1).
Physiological significance of the IFN-γ γ-mediated
regulation of RANKL signaling
It has recently been found that activated T cells promote
osteoclastogenesis through expression of RANKL and
regulate bone loss in autoimmune arthritis [18]. The
results presented above revealed that activated T cells
can also negatively affect osteoclastogenesis through
IFN-γ production. It is likely that the balance between the
actions of RANKL and of IFN-γ may regulate osteoclast
formation. For example, during acute immune reactions, an
enhanced production of IFN-γ counterbalances the aug-
mentation of RANKL expression and reduces aberrant for-
mation of osteoclasts. On the other hand, in chronic
synovitis of rheumatoid arthritis, this balance may be
skewed in favor of RANKL expression. In this context, it is
noteworthy that expression of IFN-γ is suppressed, despite
a significant infiltration of T cells [27,28], in the arthritic
joints in which RANKL expression is enhanced. Thus, the
paucity of IFN-γ and the enhanced expression of RANKL
may contribute to the activation of osteoclastogenesis in
arthritis. It is clear that other factors must be taken into
consideration in the control of osteoclastogenesis in
arthritis, e.g. RANKL induction in IL-1-stimulated or TNF-α-
stimulated synovial fibroblasts [3,29], and local cytokine
production pattern regulated by differentiation status of T
cells into Th1 or Th2 type.
Autoregulation of RANKL signaling by IFN-β β
induction and the critical role of IFN-β β in
bone metabolism
Involvement of the IFN-γ γ system in the regulation of
bone remodeling
During our study to analyze genes induced by RANKL, we
noted induction of mRNAs known to be commonly
induced by IFN-α/β. Although the integral role of the
IFN-α/β system in the immune system has been exten-
sively documented, it was unknown whether this system is
linked to RANKL signaling. To investigate the physiologi-
cal role of the IFN system in the control of bone homeosta-
sis, we studied the skeletal system of mice deficient in one
of the IFN receptor components, IFNAR1 (IFNAR1–/–
mice) [30]. Surprisingly, a notable reduction of trabecular
bone mass, a characteristic feature of osteoporosis, was
observed in the mutant mice. Concomitantly, the number
of osteoclasts was notably greater in the bone of the
IFNAR1–/– mice than in the wild-type mice. Quantitative
bone morphometric analyses further revealed a significant
decrease in the trabecular bone volume, a feature that is
diagnostic for enhanced osteoclastic bone resorption,
without any remarkable difference in the markers of
osteoblastic bone formation, indicating that the IFN-α/β
signaling is physiologically critical for maintaining the
normal bone mass by regulating osteoclastic bone resorp-
tion. RANKL-induced osteoclast formation in vitro is
remarkably enhanced in BMMs from IFNAR1–/– mice,
whereas no difference was seen in the osteoblast differen-
tiation between cultured calvarial cells from wild-type mice
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Figure 1
Signaling crosstalk between RANKL and IFNs. IFN-γ and IFN-β inhibit RANKL signaling by downregulating essential mediators of
osteoclastogenesis (TRAF6 and c-Fos, respectively). (See [8,30], and text for the details). Fra, fos-related antigen; IRF, interferon regulatory factor;
ISGF3, interferon-stimulated gene factor-3; JNK, c-Jun N-terminal kinase; NF-κB, nuclear factor κB; OPG, osteoprotegerin; RANK, receptor
activator of nuclear factor κB; Stat, signal transducer and activator of transcription; TRAF, TNF receptor-associated factor.S230
and those from IFNAR1–/– mice. We deduce that the
enhanced osteoclastogenesis in IFNAR1–/– mice is due to
a cell-autonomous abnormality of BMMs.
Induction of the IFN-β β gene by RANKL and the role of
IFN-β β in bone homeostasis
Stimulation by RANKL resulted in the induction of mRNA
of IFN-β, but not of IFN-α, in BMMs. The findings suggest
that, unlike the common action of these two IFN subtypes
against viral infection, IFN-β is selectively involved in this
osteoclast regulation (although the level of induction of
mRNA was much lower than in virus-induced cells). When
the skeletal system of the mice lacking IFN-β (IFN-β–/–
mice) was examined, these mice also exhibited severe
osteopenia resulting from enhanced osteoclastogenesis,
an observation that indicates the role of RANKL-induced
IFN-β in bone homeostasis.
Recombinant mouse IFN-β has a remarkably strong
inhibitory effect on osteoclastogenesis induced by RANKL
in combination with macrophage-colony-stimulating factor:
the effect was observed at a concentration as low as one
unit ml–1. IFN-β (as well as IFN-α) invokes cellular
responses through activation/induction of transcription
factors; these include ISGF3 [a heteromeric complex con-
sisting of signal transducer and activator of transcription 1
(STAT1), STAT2 and interferon regulatory factor 9
(IRF-9)], STAT1 homodimer and IRF-1 [25,26]. It was
found that the inhibitory action of IFN-β is abrogated in
BMMs from mice lacking STAT1 or IRF-9, indicating that
the inhibitory action is linked to the ISGF3-mediated gene
induction pathway (see Fig. 1).
To assess the efficacy of IFN-β for the suppression of
osteoclast-mediated pathological conditions, an endo-
toxin-induced model of inflammatory bone destruction in
mice was used [30]. Daily administration of IFN-β into the
inflamed site markedly inhibited the osteoclast formation
and bone resorption, indicating that IFN-β does indeed
have a beneficial effect on bone destruction, most likely by
downregulating osteoclastogenesis.
Signaling crosstalk between RANKL and IFN-β β vying for
c-Fos
To identify the downstream effector(s) of RANKL signaling
affected by the IFN-β signaling, we first carried out
immunoblot analysis of the effector molecules of RANKL
signaling in IFN-β-treated BMMs and found that expression
of c-Fos was selectively and dramatically downregulated. To
examine further whether the inhibitory action of IFN-β is
mediated through downregulation of c-Fos expression, c-
Fos was artificially expressed by retrovirus-mediated gene
transfer in BMMs. More than 50% of the virus-infected cells
underwent differentiation in the presence of IFN-β, under
condition in which fewer than 5% of cells did so when
infected by either the control virus or virus expressing c-Jun.
What is the mechanism underlying the inhibition of c-Fos
expression by IFN-β? Interestingly, the RANKL-induced
Fos mRNA was not significantly altered by IFN-β, suggest-
ing a post-transcriptional control mechanism(s). To gain
further insights into the mechanism of c-Fos suppression
by IFN-β, the synthesis of the c-Fos protein was studied
by pulse–chase experiments [30], and it was found that
the synthesis of c-Fos protein is inhibited in IFN-β-treated
BMMs. It is not yet fully understood which target genes
are responsible for suppression of c-Fos expression by
IFN-β, but we have evidence that the ISGF3-inducible
dsRNA-activated protein kinase (PKR) is responsible,
albeit partly, for the suppression.
Requirement of c-Fos itself in the RANKL induction of
the IFN-β β gene
The induction of the IFN-α/β gene in virally infected cells
requires two IRF transcription factors, IRF-3 and IRF-7
[31]. In the case of IFN-β, induction has also been known
to depend on NF-κB (which is also activated by RANKL)
[32]. Interestingly, when RANKL-induced expression of
IFN-β mRNA was studied in BMMs from mice lacking c-
Fos, or both IRF-3 and IRF-9, expression of this mRNA
was no longer observed in the absence of c-Fos but was
still detected in the absence of the IRFs critical for the
virus-mediated induction. Furthermore, stimulation with
RANKL induced a significant activation of the IFN-β pro-
moter, as revealed by a reporter-gene transfection assay,
and this activation was abrogated in cells from c-Fos-defi-
cient mice. Thus, the RANKL-induced c-Fos per se
induces its own inhibitor gene, IFN-β.
Conclusions and future prospects
Immune response is essential for host defense, but its pro-
longed or aberrant activation under certain autoimmune
conditions often results in tissue destruction mediated by
effector cells. As described here, a new biological function
of IFN-γ was discovered: to protect against destruction of
calcified tissue on T-cell activation [8]. The disease-limit-
ing effect of IFN-γ in autoimmune arthritis may be
explained, at least in part, by its potent suppressive effect
on osteoclast development. Although the clinical applica-
tion of IFN-γ has been difficult, probably because of its
disease-promoting effect at the onset phase of autoimmu-
nity [33], our results suggest that TRAF6, the critical
target of IFN-γ-mediated suppression of osteoclastogene-
sis, could be a possible molecular target of pharmacologi-
cal intervention in inflammatory bone diseases.
Our study also revealed a hitherto unknown signaling
crosstalk between RANKL and IFN-β system, which is criti-
cal for bone homeostasis [30]. This crosstalk is unique in
that RANKL signaling per se is responsible for the induc-
tion of IFN-β, and that c-Fos, the positive regulator of
RANKL signaling, is required for the induction of its own
inhibitor (see Fig. 1). In view of the osteoporotic phenotype
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found in mice lacking IFN-β or its receptor, we believe that
this novel, negative-feedback regulation mechanism is
physiologically important for maintaining bone mass. In
this context, it would be interesting to find out if the nega-
tive regulation of osteoclastogenesis by IFN-β is modu-
lated in osteopenic disease conditions.
Although further study is needed, the series of observa-
tions on the novel role of IFN-β may offer new therapeutic
approaches to bone diseases such as inflammation-
induced bone destruction and osteoporosis. In fact,
exogenous application of IFN-β indeed has a beneficial
effect against bone destruction in the lipopolysaccharide-
induced model, most likely by downregulation of osteo-
clastogenesis. Our preliminary results also suggest that
the systemic administration of IFN-β can reverse bone loss
in an osteoporosis model of ovariectomized mice. In addi-
tion, identification of the critical target gene(s) of IFN-β
responsible for the suppression of osteoclastogenesis
may provide further insights into the regulation of bone
remodeling.
Glossary of terms
BMM = bone-marrow-derived monocyte/macrophage pre-
cursor cell; GAF = IFN-γ-activated factor; IFNAR = inter-
feron-α/β receptor; IFNGR = interferon-γ receptor; IRF =
interferon regulatory factor; ISGF3 = interferon-stimulated
gene factor 3; JNK = c-Jun N-terminal kinase; OPG =
osteoprotegerin; RANK = receptor activator of nuclear
factor κB; RANKL = receptor activator of nuclear factor
κB ligand; TRAF = TNF receptor-associated factor.
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